Tenderwize
Zurück zur Suche

Drug Discount Agreements for Various Active Substances (Open-House)

AOK NordWest - Die Gesundheitskasse·Dortmund, Germany·Deadline Jun 24, 2027 · 303 days left·Open·Supplies
Registrieren zum SpeichernOpen documents
Structured notice only
Originaltitel der Bekanntmachung

Germany – Pharmaceutical products – Arzneimittel-Rabattverträge ab 01.09.2025 zu diversen Wirkstoffen im Rahmen eines Open-House-Verfahrens

50/100

Opportunity Score

Needs reviewLow complexity
SuppliesOpen
Warum diese Bewertung?

Chance

50 / 100

Komplexität

20 / 100

Risikofaktoren

Buyer retains right to award exclusive contracts later, which will suspend these open-house agreements. Typically 8-10...

No documented procurement documents analyzed; may contain additional obligations not covered in notice.

Tiefe Portfolioanalyse

Tiefe Analyse der Unternehmenspassung

Verwendet:

  • Description
  • Industries & Services
  • Capabilities
  • Market & Experience
  • Certifications

Überblick

Moderate opportunity

Wichtige Fakten

  • Supplies contract
  • 1 lot
  • Duration until Aug 2027
  • Supply of pharmaceutical products (discount agreements) for seven active substances: Budesonide (oral 4mg), Eltrombopag, Fluorouracil (cream), Mebeverine, Nilotinib, Rotigotine, Umeclidinium bromide.
  • Open-house model: any eligible pharmaceutical entrepreneur can join at any time during the contract period.
Vollständige Zusammenfassung anzeigen

The tender is an open-house procedure for drug discount agreements (Rabattverträge) under §130a Abs. 8 SGB V for seven active substances: Budesonide (oral, 4mg), Eltrombopag, Fluorouracil (cream), Mebeverine, Nilotinib, Rotigotine, and Umeclidinium bromide. The buyer is AOK NordWest. The procedure is not a public procurement under EU directives (per EuGH C-410/14) but published voluntarily. The contract duration is up to 24 months starting 01.09.2025. All eligible pharmaceutical entrepreneurs can join at any time. No estimated value or award criteria are specified. Electronic submission is not allowed; applications are via email. The deadline for submission is 24.06.2027, 23:59 (but continuous accession is possible).

Risiken

Buyer retains right to award exclusive contracts later, which will suspend these open-house agreements. Typically 8-10...

No documented procurement documents analyzed; may contain additional obligations not covered in notice.

Analyse kann unvollständig sein

Nur ein Teil der Vergabeunterlagen wurde analysiert. Weitere Anforderungen, Zertifikate oder Einreichungsdokumente können in den übrigen Unterlagen enthalten sein.

Wichtige Anforderungen

Technical

  • Must be a pharmaceutical entrepreneur as defined in §4 Abs. 18 AMG for the offered medicinal products, throughout the contract duration.
  • Application via email to [email protected].

Administrative

  • Uniform contract conditions; no individual negotiations.

Anforderungen können unvollständig sein.

Auftraggeber

Ort

Dortmund, DEU

Website

www.aok.de

Kennung

DE124159739

Tätigkeit

Health

Lose (1)

LOT-0001

Drug Discount Agreements for Various Active Substances (Open-House)

All eligible pharmaceutical entrepreneurs can conclude discount agreements for the listed active substances under uniform conditions. The contract runs max. 24 months from 01.09.2025. There is no exclusivity; the buyer may later award exclusive contracts that suspend these agreements.

SuppliesEU fundedElectronic submission

Ort

Hagen, Germany

Dauer

Aug 2025 - Aug 2027

Kategorie

Pharmaceutical products

Frist

Deadline Jun 24, 2027

Vergabedetails

Veröffentlichungsdatum
17 Jul 2025
Sprachen
German

Referenzmetadaten

Rechtsgrundlage
32014L0024

Referenz-IDs

Ausschreibungs-ID
470057-2025

Dokumente (1)

Vergabedokument 1

Ähnliche Ausschreibungen

Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells über Arzneimittel mit dem Handelsnamen Orylmyte(R) (ATC-Code nach WHO: V01AA03)

Aug 31

Bulgaria – Pharmaceutical products – Динамична система за покупки за доставка на лекарствени продукти за Медицински институт на МВР

Jul 9

Belgium – Pharmaceutical products – Antimycotica

Aug 27

Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells über Arzneimittel mit dem Handelsnamen Oralair(R) (ATC-Code nach WHO: V01AA02)

Aug 31

Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells zum Wirkstoff Ipratropiumbromid (ATC-Code nach WHO: R03BB01)

Sep 30

Denmark – Pharmaceutical products – Amgros 2027 1.1170.a

Sep 3